首页 > 最新文献

Medical Sciences最新文献

英文 中文
034861500 034861500
Pub Date : 2024-05-05 DOI: 10.53453/ms.2024.5.10
{"title":"034861500","authors":"","doi":"10.53453/ms.2024.5.10","DOIUrl":"https://doi.org/10.53453/ms.2024.5.10","url":null,"abstract":"","PeriodicalId":18539,"journal":{"name":"Medical Sciences","volume":"223 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141013038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
035115500 035115500
Pub Date : 2024-05-05 DOI: 10.53453/ms.2024.5.1
{"title":"035115500","authors":"","doi":"10.53453/ms.2024.5.1","DOIUrl":"https://doi.org/10.53453/ms.2024.5.1","url":null,"abstract":"","PeriodicalId":18539,"journal":{"name":"Medical Sciences","volume":"295 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141012287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
035306000 035306000
Pub Date : 2024-05-05 DOI: 10.53453/ms.2024.5.2
{"title":"035306000","authors":"","doi":"10.53453/ms.2024.5.2","DOIUrl":"https://doi.org/10.53453/ms.2024.5.2","url":null,"abstract":"","PeriodicalId":18539,"journal":{"name":"Medical Sciences","volume":"294 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141012293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive Factors of Therapy-Related Cardiovascular Events in Patients with Lymphoma Receiving Anthracyclines 接受蒽环类药物治疗的淋巴瘤患者发生治疗相关心血管事件的预测因素
Pub Date : 2024-04-24 DOI: 10.3390/medsci12020023
A. López-García, Ester Macia, Sandra Gómez-Talavera, Eva Castillo, D. Morillo, Jose Tuñon, Borja Ibañez, R. Córdoba
Background: Cancer-therapy-related cardiac dysfunction (CTRCD) is a growing concern for public health, with a growing incidence due to improved survival rates of patients with hematological malignancies due to diagnostic and therapeutic advances. The identification of patients at risk for CTRCD is vital to developing preventive strategies. Methods: A single-center retrospective cohort study was conducted between 1 January 2017 and 15 February 2023. Medical records of patients with lymphoma treated with first-line anthracyclines were reviewed. Demographic data, cardiovascular risk factors, biomarkers of myocardial damage, and echocardiographic information were collected. Results: A total of 200 patients were included. The incidence of CTRCD was 17.4% (35/200). Patients with CTRCD were older than those without CTRCD, with a mean age of 65.17 years vs. 56.77 (p = 0.008). Dyslipidemia (DL) (31.4% vs. 13.4% p = 0.017) and previous cardiovascular disease (40% vs. 13.3%; p < 0.001) were more frequent in the group who developed an event. Mean baseline NT-proBNP levels in the subgroup with cardiovascular events were 388.73 kg/L ± 101.02, and they were 251.518 kg/L ± 26.22 in those who did not (p = 0.004). Differences in Troponin I levels were identified during and after treatment without exceeding the laboratory’s upper reference limit. Patients were followed for a median of 51.83 months (0.76–73.49). The presence of a CTCRD event had a negative impact on overall mortality from any cause (HR = 2.23 (95% CI: 1.08–2.93); p = 0.031). Conclusions: Early identification of risk factors is crucial to manage patients at risk for CTRCD.
背景:由于诊断和治疗方法的进步,血液恶性肿瘤患者的存活率有所提高,因此癌症治疗相关心功能不全(CTRCD)的发病率也在不断上升。识别有 CTRCD 风险的患者对于制定预防策略至关重要。方法:在 2017 年 1 月 1 日至 2023 年 2 月 15 日期间开展了一项单中心回顾性队列研究。研究人员查阅了接受一线蒽环类药物治疗的淋巴瘤患者的病历。收集了人口统计学数据、心血管风险因素、心肌损伤生物标志物和超声心动图信息。研究结果共纳入 200 名患者。CTRCD的发病率为17.4%(35/200)。CTRCD 患者的年龄大于非 CTRCD 患者,平均年龄为 65.17 岁对 56.77 岁(P = 0.008)。血脂异常(DL)(31.4% 对 13.4%,P = 0.017)和既往患有心血管疾病(40% 对 13.3%,P < 0.001)在发生事件的组别中更为常见。发生心血管事件亚组的平均基线 NT-proBNP 水平为 388.73 kg/L ± 101.02,未发生心血管事件亚组的平均基线 NT-proBNP 水平为 251.518 kg/L ± 26.22(P = 0.004)。在治疗期间和治疗后,发现肌钙蛋白 I 水平存在差异,但未超过实验室参考上限。患者的随访时间中位数为 51.83 个月(0.76-73.49 个月)。出现 CTCRD 事件对任何原因导致的总死亡率均有负面影响(HR = 2.23(95% CI:1.08-2.93);P = 0.031)。结论早期识别风险因素对于管理有 CTRCD 风险的患者至关重要。
{"title":"Predictive Factors of Therapy-Related Cardiovascular Events in Patients with Lymphoma Receiving Anthracyclines","authors":"A. López-García, Ester Macia, Sandra Gómez-Talavera, Eva Castillo, D. Morillo, Jose Tuñon, Borja Ibañez, R. Córdoba","doi":"10.3390/medsci12020023","DOIUrl":"https://doi.org/10.3390/medsci12020023","url":null,"abstract":"Background: Cancer-therapy-related cardiac dysfunction (CTRCD) is a growing concern for public health, with a growing incidence due to improved survival rates of patients with hematological malignancies due to diagnostic and therapeutic advances. The identification of patients at risk for CTRCD is vital to developing preventive strategies. Methods: A single-center retrospective cohort study was conducted between 1 January 2017 and 15 February 2023. Medical records of patients with lymphoma treated with first-line anthracyclines were reviewed. Demographic data, cardiovascular risk factors, biomarkers of myocardial damage, and echocardiographic information were collected. Results: A total of 200 patients were included. The incidence of CTRCD was 17.4% (35/200). Patients with CTRCD were older than those without CTRCD, with a mean age of 65.17 years vs. 56.77 (p = 0.008). Dyslipidemia (DL) (31.4% vs. 13.4% p = 0.017) and previous cardiovascular disease (40% vs. 13.3%; p < 0.001) were more frequent in the group who developed an event. Mean baseline NT-proBNP levels in the subgroup with cardiovascular events were 388.73 kg/L ± 101.02, and they were 251.518 kg/L ± 26.22 in those who did not (p = 0.004). Differences in Troponin I levels were identified during and after treatment without exceeding the laboratory’s upper reference limit. Patients were followed for a median of 51.83 months (0.76–73.49). The presence of a CTCRD event had a negative impact on overall mortality from any cause (HR = 2.23 (95% CI: 1.08–2.93); p = 0.031). Conclusions: Early identification of risk factors is crucial to manage patients at risk for CTRCD.","PeriodicalId":18539,"journal":{"name":"Medical Sciences","volume":"17 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140661609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What about the Use of Ice Cream as a Supplementary Diet in Chronic Kidney Disease? A Case–Control Study 将冰淇淋作为慢性肾病患者的辅助饮食如何?病例对照研究
Pub Date : 2024-04-23 DOI: 10.3390/medsci12020022
Daniela Metro, F. Corallo, Davide Cardile, G. Gembillo, Luigi Manasseri, Domenico Santoro, Martina Buda, R. S. Calabrò, L. Bonanno
Maintaining a healthy lifestyle can extend life expectancy and improve a person’s health status. In addition to physical activity and bad habits related to smoking and alcohol, diet is also a determining factor. Following a healthy diet pattern over time and supporting a healthy body weight contributes to reducing the risk of developing more severe complications associated with very common diseases such as chronic kidney disease (CKD), diabetes, or cardiovascular diseases. The 2015–2020 Dietary Guidelines for Americans promote the adoption of fat-free or low-fat diets and discourage the consumption of foods with added sugar and solid fats, such as ice creams and other frozen desserts. On the other hand, ice cream, from a nutritional and healthy point of view, can be considered a possible food choice, due to its greater palatability and high nutritional content, but its consumption must be scheduled in a balanced diet. In this retrospective study, 36 patients with chronic renal failure were enrolled. Two different diets were proposed (A and B). In Diet B, lemon sorbet was added twice a week as an alternative food to replace fruit or snacks making the diet more varied and palatable. Nutritional status and biohumoral, immunological, and blood parameters were evaluated after 6 months. A statistical analysis shows a significant inter-group difference in creatinine and azotemia between T0 and T1. Intra-group significant differences were found in lymphocytes (p = 0.005) and azotemia (p < 0.001) in Diet A, and in azotemia (p < 0.001) and transferrin (p < 0.001) in Diet B. The results indicated that ice cream represented a good alternative food in both groups of patients regarding nutritional values and patient satisfaction. Furthermore, the treatment with ice cream allowed for better control of azotemia, maintaining stable levels even in patients with advanced CKD. This study concludes that ice cream could exert beneficial effects in addition to CKD patients’ dietary regimens.
保持健康的生活方式可以延长人的寿命,改善人的健康状况。除了体育锻炼和与烟酒有关的不良习惯外,饮食也是一个决定性因素。长期坚持健康的饮食模式并保持健康的体重,有助于降低患上慢性肾病(CKD)、糖尿病或心血管疾病等常见疾病相关的更严重并发症的风险。2015-2020 年美国人膳食指南》提倡采用无脂或低脂饮食,不鼓励食用添加糖和固体脂肪的食品,如冰淇淋和其他冷冻甜点。另一方面,从营养和健康的角度来看,冰淇淋因其口味更佳、营养成分更高,可被视为一种可能的食物选择,但必须在均衡饮食的基础上安排食用。在这项回顾性研究中,共招募了 36 名慢性肾衰竭患者。提出了两种不同的饮食方案(A 和 B)。在饮食 B 中,每周添加两次柠檬冰沙,作为替代水果或点心的食物,使饮食更加多样化和可口。6 个月后,对营养状况、生物体液、免疫和血液参数进行了评估。统计分析显示,T0 和 T1 组间肌酐和氮质血症差异显著。结果表明,就营养价值和患者满意度而言,冰淇淋在两组患者中都是很好的替代食品。此外,使用冰淇淋治疗能更好地控制氮质血症,即使是晚期慢性肾脏病患者也能保持稳定的氮质血症水平。这项研究的结论是,冰淇淋可在慢性肾脏病患者的饮食疗法之外发挥有益作用。
{"title":"What about the Use of Ice Cream as a Supplementary Diet in Chronic Kidney Disease? A Case–Control Study","authors":"Daniela Metro, F. Corallo, Davide Cardile, G. Gembillo, Luigi Manasseri, Domenico Santoro, Martina Buda, R. S. Calabrò, L. Bonanno","doi":"10.3390/medsci12020022","DOIUrl":"https://doi.org/10.3390/medsci12020022","url":null,"abstract":"Maintaining a healthy lifestyle can extend life expectancy and improve a person’s health status. In addition to physical activity and bad habits related to smoking and alcohol, diet is also a determining factor. Following a healthy diet pattern over time and supporting a healthy body weight contributes to reducing the risk of developing more severe complications associated with very common diseases such as chronic kidney disease (CKD), diabetes, or cardiovascular diseases. The 2015–2020 Dietary Guidelines for Americans promote the adoption of fat-free or low-fat diets and discourage the consumption of foods with added sugar and solid fats, such as ice creams and other frozen desserts. On the other hand, ice cream, from a nutritional and healthy point of view, can be considered a possible food choice, due to its greater palatability and high nutritional content, but its consumption must be scheduled in a balanced diet. In this retrospective study, 36 patients with chronic renal failure were enrolled. Two different diets were proposed (A and B). In Diet B, lemon sorbet was added twice a week as an alternative food to replace fruit or snacks making the diet more varied and palatable. Nutritional status and biohumoral, immunological, and blood parameters were evaluated after 6 months. A statistical analysis shows a significant inter-group difference in creatinine and azotemia between T0 and T1. Intra-group significant differences were found in lymphocytes (p = 0.005) and azotemia (p < 0.001) in Diet A, and in azotemia (p < 0.001) and transferrin (p < 0.001) in Diet B. The results indicated that ice cream represented a good alternative food in both groups of patients regarding nutritional values and patient satisfaction. Furthermore, the treatment with ice cream allowed for better control of azotemia, maintaining stable levels even in patients with advanced CKD. This study concludes that ice cream could exert beneficial effects in addition to CKD patients’ dietary regimens.","PeriodicalId":18539,"journal":{"name":"Medical Sciences","volume":"136 16","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140668668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maternal Diabetes Mellitus and Neonatal Outcomes in Bisha: A Retrospective Cohort Study 比沙的孕产妇糖尿病与新生儿结局:回顾性队列研究
Pub Date : 2024-04-15 DOI: 10.3390/medsci12020021
Abdullah Alshomrany, Elhadi Miskeen, Jaber A. Alfaifi, Hassan Alshamrani, Abdulmohsen Alshahrani
Background: Maternal diabetes mellitus (MDM) is associated with increased risks for adverse neonatal outcomes. However, the impact of MDM on neonatal outcomes in Bisha, a city in Saudi Arabia, is not well documented. This study aims to investigate the impact of MDM on neonatal outcomes in the Maternity and Children’s Hospital (MCH), Bisha, Saudi Arabia. Methods: A retrospective cohort study was conducted on 181 pregnant women with diabetes and their neonates who were diagnosed at the Maternity and Children’s Hospital (MCH), Bisha, Saudi Arabia, between 5 October 2020 and 5 November 2022. The primary outcome was a composite of adverse neonatal outcomes, including stillbirth, neonatal death, macrosomia, preterm birth, respiratory distress syndrome, hypoglycemia, and congenital anomalies. Logistic regression analyses were used to adjust for potential confounders. Results: The total sample size was 181. The average age of patients was 34 years (SD = 6.45). The majority of the patients were diagnosed with GDM, 147 (81.2%), and pre-GDM, 34 (18.8%). Neonates born to mothers with MDM had a higher risk of adverse neonatal outcomes compared to those born to mothers without MDM (adjusted odds ratio [aOR] = 1.46, 95% confidence interval [CI]: 1.25–1.70). The risks of macrosomia (aOR = 1.74, 95% CI: 1.38–2.19), LBW (aOR = 1.32, 95% CI: 1.06–1.66), and RDS (aOR = 1.57, 95% CI: 1.28–1.93) were significantly higher among neonates born to mothers with MDM. The types of DM were statistically significant in terms of their correlation with the following neonatal outcomes: hypoglycemia (p-value = 0.017), macrosomia (p-value = 0.050), and neonatal death (p-value = 0.017). Conclusions: MDM is associated with an increased risk of adverse neonatal outcomes in Bisha. The early identification and management of MDM may improve neonatal outcomes and reduce the burden of neonatal morbidity and mortality in this population.
背景:产妇糖尿病(MDM)与新生儿不良预后的风险增加有关。然而,在沙特阿拉伯的一个城市比沙(Bisha),MDM 对新生儿预后的影响还没有很好的记录。本研究旨在调查 MDM 对沙特阿拉伯比沙妇幼医院(MCH)新生儿预后的影响。研究方法对 2020 年 10 月 5 日至 2022 年 11 月 5 日期间在沙特阿拉伯比沙妇幼医院(MCH)确诊的 181 名糖尿病孕妇及其新生儿进行了回顾性队列研究。主要结果是新生儿不良结局的综合,包括死产、新生儿死亡、巨大儿、早产、呼吸窘迫综合征、低血糖和先天性畸形。采用逻辑回归分析调整潜在的混杂因素。结果样本总数为 181 例。患者平均年龄为 34 岁(SD = 6.45)。大多数患者被确诊为 GDM(147 例,占 81.2%),GDM 前期(34 例,占 18.8%)。与母亲未患甲胎蛋白血症的新生儿相比,母亲患甲胎蛋白血症的新生儿发生不良新生儿结局的风险更高(调整后的几率比 [aOR] = 1.46,95% 置信区间 [CI]:1.25-1.70)。患有 MDM 的母亲所生的新生儿发生巨大儿(aOR = 1.74,95% CI:1.38-2.19)、低体重儿(aOR = 1.32,95% CI:1.06-1.66)和 RDS(aOR = 1.57,95% CI:1.28-1.93)的风险明显更高。DM类型与以下新生儿结局的相关性具有统计学意义:低血糖(P值=0.017)、巨大儿(P值=0.050)和新生儿死亡(P值=0.017)。结论在比沙,MDM 与新生儿不良结局的风险增加有关。早期识别和处理 MDM 可改善新生儿预后,降低新生儿发病率和死亡率。
{"title":"Maternal Diabetes Mellitus and Neonatal Outcomes in Bisha: A Retrospective Cohort Study","authors":"Abdullah Alshomrany, Elhadi Miskeen, Jaber A. Alfaifi, Hassan Alshamrani, Abdulmohsen Alshahrani","doi":"10.3390/medsci12020021","DOIUrl":"https://doi.org/10.3390/medsci12020021","url":null,"abstract":"Background: Maternal diabetes mellitus (MDM) is associated with increased risks for adverse neonatal outcomes. However, the impact of MDM on neonatal outcomes in Bisha, a city in Saudi Arabia, is not well documented. This study aims to investigate the impact of MDM on neonatal outcomes in the Maternity and Children’s Hospital (MCH), Bisha, Saudi Arabia. Methods: A retrospective cohort study was conducted on 181 pregnant women with diabetes and their neonates who were diagnosed at the Maternity and Children’s Hospital (MCH), Bisha, Saudi Arabia, between 5 October 2020 and 5 November 2022. The primary outcome was a composite of adverse neonatal outcomes, including stillbirth, neonatal death, macrosomia, preterm birth, respiratory distress syndrome, hypoglycemia, and congenital anomalies. Logistic regression analyses were used to adjust for potential confounders. Results: The total sample size was 181. The average age of patients was 34 years (SD = 6.45). The majority of the patients were diagnosed with GDM, 147 (81.2%), and pre-GDM, 34 (18.8%). Neonates born to mothers with MDM had a higher risk of adverse neonatal outcomes compared to those born to mothers without MDM (adjusted odds ratio [aOR] = 1.46, 95% confidence interval [CI]: 1.25–1.70). The risks of macrosomia (aOR = 1.74, 95% CI: 1.38–2.19), LBW (aOR = 1.32, 95% CI: 1.06–1.66), and RDS (aOR = 1.57, 95% CI: 1.28–1.93) were significantly higher among neonates born to mothers with MDM. The types of DM were statistically significant in terms of their correlation with the following neonatal outcomes: hypoglycemia (p-value = 0.017), macrosomia (p-value = 0.050), and neonatal death (p-value = 0.017). Conclusions: MDM is associated with an increased risk of adverse neonatal outcomes in Bisha. The early identification and management of MDM may improve neonatal outcomes and reduce the burden of neonatal morbidity and mortality in this population.","PeriodicalId":18539,"journal":{"name":"Medical Sciences","volume":"89 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140702761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer 索拉非尼疗法治疗非小细胞肺癌的疗效
Pub Date : 2024-04-07 DOI: 10.3390/medsci12020020
Morgann Hendrixson, Yevgeniy Gladkiy, A. Thyagarajan, Ravi P. Sahu
Lung cancer remains the leading cause of cancer-related deaths, with a poor prognosis. Of the two types, non-small cell lung cancer (NSCLC) is the major and most prevalent type and associated with low response rates to the current treatment options. Sorafenib, a multitargeted tyrosine kinase inhibitor used for various malignancies, gained attention for its potential efficacy in NSCLC. This review paper focuses on the findings of recent in vitro, in vivo, and clinical studies regarding the efficacy of sorafenib. Overall, sorafenib has shown definitive therapeutic potential in NSCLC cell lines, xenografts, and human subjects. Novel approaches to sorafenib delivery may improve its efficacy and should be the focus of further studies.
肺癌仍然是癌症相关死亡的主要原因,而且预后较差。在两种类型的肺癌中,非小细胞肺癌(NSCLC)是最主要和最常见的类型,而且对现有治疗方案的反应率很低。索拉非尼是一种多靶点酪氨酸激酶抑制剂,可用于多种恶性肿瘤,因其对NSCLC的潜在疗效而备受关注。本综述论文重点介绍了近期有关索拉非尼疗效的体外、体内和临床研究结果。总的来说,索拉非尼在 NSCLC 细胞系、异种移植物和人体受试者中显示出了明确的治疗潜力。索拉非尼给药的新方法可能会提高其疗效,应成为进一步研究的重点。
{"title":"Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer","authors":"Morgann Hendrixson, Yevgeniy Gladkiy, A. Thyagarajan, Ravi P. Sahu","doi":"10.3390/medsci12020020","DOIUrl":"https://doi.org/10.3390/medsci12020020","url":null,"abstract":"Lung cancer remains the leading cause of cancer-related deaths, with a poor prognosis. Of the two types, non-small cell lung cancer (NSCLC) is the major and most prevalent type and associated with low response rates to the current treatment options. Sorafenib, a multitargeted tyrosine kinase inhibitor used for various malignancies, gained attention for its potential efficacy in NSCLC. This review paper focuses on the findings of recent in vitro, in vivo, and clinical studies regarding the efficacy of sorafenib. Overall, sorafenib has shown definitive therapeutic potential in NSCLC cell lines, xenografts, and human subjects. Novel approaches to sorafenib delivery may improve its efficacy and should be the focus of further studies.","PeriodicalId":18539,"journal":{"name":"Medical Sciences","volume":"16 30","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140732804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Automated Single-Sperm Selection Software (SiD) during ICSI: A Prospective Sibling Oocyte Evaluation ICSI 期间的自动单精子选择软件 (SiD):同胞卵母细胞前瞻性评估
Pub Date : 2024-03-27 DOI: 10.3390/medsci12020019
Debbie Montjean, Marie-Hélène Godin Pagé, Carmen Pacios, Annabelle Calvé, Ghenima Hamiche, Moncef Benkhalifa, Pierre Miron
The computer-assisted program SiD was developed to assess and select sperm in real time based on motility characteristics. To date, there are limited studies examining the correlation between AI-assisted sperm selection and ICSI outcomes. To address this limit, a total of 646 sibling MII oocytes were randomly divided into two groups as follows: the ICSI group (n = 320): ICSI performed with sperm selected by the embryologist and the ICSI-SiD group (n = 326): ICSI performed with sperm selected using SiD software. Our results show a non-significant trend towards improved outcomes in the ICSI-SiD group across various biological parameters, including fertilization, cleavage, day 3 embryo development, blastocyst development, and quality on day 5. Similarly, we observed a non-significant increase in these outcomes when comparing both groups with sperm selection performed by a junior embryologist. Embryo development was monitored using a timelapse system. Some fertilization events happen significantly earlier when SiD is used for ICSI, but no significant difference was observed in the ICSI-SiD group for other timepoints. We observed comparable cumulative early and clinical pregnancy rates after ICSI-SiD. This preliminary investigation illustrated that employing the automated sperm selection software SiD leads to comparable biological outcomes, suggesting its efficacy in sperm selection.
计算机辅助程序SiD的开发是为了根据精子的活力特征实时评估和选择精子。迄今为止,对人工授精辅助精子选择与卵胞浆内单精子显微注射结果之间相关性的研究还很有限。为了解决这一局限性,我们将总共 646 个同胞 MII 卵母细胞随机分为以下两组:ICSI 组(n = 320):ICSI-SiD组(n = 326):ICSI-SiD组(n = 326):使用SiD软件选择精子进行ICSI。我们的结果显示,ICSI-SiD 组在受精、裂解、第 3 天胚胎发育、囊胚发育和第 5 天胚胎质量等各种生物学参数方面的结果均有改善,但趋势并不显著。同样,在比较两组与由初级胚胎学家进行的精子选择时,我们观察到上述结果均无显著提高。胚胎发育采用延时系统进行监测。当使用 SiD 进行 ICSI 时,一些受精事件会明显提前发生,但在其他时间点上,ICSI-SiD 组没有观察到显著差异。我们观察到,ICSI-SiD 后的累积早孕率和临床妊娠率相当。这项初步调查表明,使用自动精子选择软件 SiD 可获得相似的生物学结果,这表明 SiD 在精子选择方面非常有效。
{"title":"Automated Single-Sperm Selection Software (SiD) during ICSI: A Prospective Sibling Oocyte Evaluation","authors":"Debbie Montjean, Marie-Hélène Godin Pagé, Carmen Pacios, Annabelle Calvé, Ghenima Hamiche, Moncef Benkhalifa, Pierre Miron","doi":"10.3390/medsci12020019","DOIUrl":"https://doi.org/10.3390/medsci12020019","url":null,"abstract":"The computer-assisted program SiD was developed to assess and select sperm in real time based on motility characteristics. To date, there are limited studies examining the correlation between AI-assisted sperm selection and ICSI outcomes. To address this limit, a total of 646 sibling MII oocytes were randomly divided into two groups as follows: the ICSI group (n = 320): ICSI performed with sperm selected by the embryologist and the ICSI-SiD group (n = 326): ICSI performed with sperm selected using SiD software. Our results show a non-significant trend towards improved outcomes in the ICSI-SiD group across various biological parameters, including fertilization, cleavage, day 3 embryo development, blastocyst development, and quality on day 5. Similarly, we observed a non-significant increase in these outcomes when comparing both groups with sperm selection performed by a junior embryologist. Embryo development was monitored using a timelapse system. Some fertilization events happen significantly earlier when SiD is used for ICSI, but no significant difference was observed in the ICSI-SiD group for other timepoints. We observed comparable cumulative early and clinical pregnancy rates after ICSI-SiD. This preliminary investigation illustrated that employing the automated sperm selection software SiD leads to comparable biological outcomes, suggesting its efficacy in sperm selection.","PeriodicalId":18539,"journal":{"name":"Medical Sciences","volume":"46 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140373511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of Endocrine and Inflammatory Markers in Preserved Ratio Impaired Spirometry 肺活量保留率受损时的内分泌和炎症标志物分析
Pub Date : 2024-03-27 DOI: 10.3390/medsci12020018
Fabíola Ramos Jesus, Anna Clara Santiago Moraes, Ingrid Lorena Neves da Silva, Fabine Correia Passos, Cristina Salles, M. Neves, Gyselle Chrystina Baccan
Chronic Obstructive Pulmonary Disease (COPD) is a disease of the lungs characterized by chronic airflow obstruction. Individuals with preserved ratio impaired spirometry (PRISm) may be at risk for developing COPD. This study aimed to characterize PRISm and COPD patients in terms of their immune response and endocrine profile to identify differences extending beyond lung function. The participants performed the clinical assessment, pulmonary function test, and blood collection to determine serum hormone levels and concentrations of cytokine. Differences were observed in the nutritional status, lung function, and comorbidity. There were no differences in IL-6, IL-8, IL-10, IL-12, and TNF levels between PRISm and COPD groups. Both PRISm and COPD patients have lower dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) levels than controls. Correlation analysis of PRISm and COPD patients revealed positive correlations between serum levels of DHEA-S and DHEA, with forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), which negatively correlated with IL-8 levels. The results indicated that despite differences in lung function parameters, the PRISm and COPD groups exhibited similarities in endocrine profile alterations. This study represents the first attempt to link endocrine with immune markers and lung function in individuals with PRISm.
慢性阻塞性肺病(COPD)是一种以慢性气流阻塞为特征的肺部疾病。肺活量保留比值受损(PRISm)的人可能有罹患慢性阻塞性肺病的风险。本研究旨在从免疫反应和内分泌特征方面描述 PRISm 和慢性阻塞性肺病患者,以确定肺功能以外的差异。参与者进行了临床评估、肺功能测试和采血,以确定血清激素水平和细胞因子浓度。在营养状况、肺功能和合并症方面观察到了差异。PRISm组和COPD组的IL-6、IL-8、IL-10、IL-12和TNF水平没有差异。PRISm 和 COPD 患者的脱氢表雄酮(DHEA)和硫酸脱氢表雄酮(DHEA-S)水平均低于对照组。对 PRISm 和慢性阻塞性肺病患者进行的相关分析表明,血清中的 DHEA-S 和 DHEA 水平与 1 秒用力呼气容积 (FEV1) 和用力肺活量 (FVC) 呈正相关,而与 IL-8 水平呈负相关。结果表明,尽管肺功能参数存在差异,但 PRISm 组和 COPD 组在内分泌特征改变方面表现出相似性。这项研究首次尝试将 PRISm 患者的内分泌、免疫标记物和肺功能联系起来。
{"title":"Analysis of Endocrine and Inflammatory Markers in Preserved Ratio Impaired Spirometry","authors":"Fabíola Ramos Jesus, Anna Clara Santiago Moraes, Ingrid Lorena Neves da Silva, Fabine Correia Passos, Cristina Salles, M. Neves, Gyselle Chrystina Baccan","doi":"10.3390/medsci12020018","DOIUrl":"https://doi.org/10.3390/medsci12020018","url":null,"abstract":"Chronic Obstructive Pulmonary Disease (COPD) is a disease of the lungs characterized by chronic airflow obstruction. Individuals with preserved ratio impaired spirometry (PRISm) may be at risk for developing COPD. This study aimed to characterize PRISm and COPD patients in terms of their immune response and endocrine profile to identify differences extending beyond lung function. The participants performed the clinical assessment, pulmonary function test, and blood collection to determine serum hormone levels and concentrations of cytokine. Differences were observed in the nutritional status, lung function, and comorbidity. There were no differences in IL-6, IL-8, IL-10, IL-12, and TNF levels between PRISm and COPD groups. Both PRISm and COPD patients have lower dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) levels than controls. Correlation analysis of PRISm and COPD patients revealed positive correlations between serum levels of DHEA-S and DHEA, with forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), which negatively correlated with IL-8 levels. The results indicated that despite differences in lung function parameters, the PRISm and COPD groups exhibited similarities in endocrine profile alterations. This study represents the first attempt to link endocrine with immune markers and lung function in individuals with PRISm.","PeriodicalId":18539,"journal":{"name":"Medical Sciences","volume":"79 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140376095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pituitary Adenoma in the Philippines: A Scoping Review on the Treatment Gaps, Challenges, and Current State of Care 菲律宾的垂体腺瘤:关于治疗差距、挑战和护理现状的范围综述
Pub Date : 2024-03-19 DOI: 10.3390/medsci12010016
Mykha Marie B. Tabuzo, Mary Angeline Luz U. Hernandez, Annabell E. Chua, Patricia D. Maningat, Harold Henrison C. Chiu, R. Jamora
Background: Pituitary adenomas are benign brain tumors that impose a heavy burden on patients worldwide. The local burden of disease is yet to be established due to scarcity of data. In line with this, this study aims to present the challenges and gaps in the treatment of pituitary adenomas in the Philippines. Methods: A scoping review of available relevant literature on epidemiology, clinical experience with treatment, health financing, and healthcare delivery system based on the Preferred Reporting Items for Systematic reviews and Meta-analysis guidelines extension for Scoping Reviews was conducted. Results: The scarcity of updated local clinical data, inequity of distribution of resources, inadequate government support, and lack of affordable diagnostic testing, medications, and neurosurgical procedures are the factors that hinder provision of adequate care of pituitary adenomas in the Philippines. Conclusion: There are notable treatment gaps in the management of pituitary adenomas in the Philippines, which may be addressed by strengthening universal healthcare. Strategies to address these gaps were proposed, including improving public-private insurance coverage, increasing manpower, enhancing accessibility to resources, and spreading more awareness.
背景:垂体腺瘤是一种良性脑肿瘤,给全球患者带来沉重负担。由于数据匮乏,当地的疾病负担尚未确定。有鉴于此,本研究旨在介绍菲律宾在治疗垂体腺瘤方面面临的挑战和存在的差距。研究方法根据《系统综述和荟萃分析首选报告项目》(Preferred Reporting Items for Systematic Review and Meta-analysis guidelines extension for Scoping Reviews),对流行病学、临床治疗经验、医疗融资和医疗服务体系等方面的现有相关文献进行了范围界定。研究结果菲律宾缺乏最新的本地临床数据、资源分配不均、政府支持不足,以及缺乏可负担得起的诊断检测、药物和神经外科手术,这些都是阻碍菲律宾为垂体腺瘤患者提供充分治疗的因素。结论菲律宾在垂体腺瘤的治疗方面存在明显的差距,这可以通过加强全民医疗保健来解决。研究人员提出了弥补这些差距的策略,包括改善公私保险的覆盖面、增加人力、提高资源的可及性以及普及更多的意识。
{"title":"Pituitary Adenoma in the Philippines: A Scoping Review on the Treatment Gaps, Challenges, and Current State of Care","authors":"Mykha Marie B. Tabuzo, Mary Angeline Luz U. Hernandez, Annabell E. Chua, Patricia D. Maningat, Harold Henrison C. Chiu, R. Jamora","doi":"10.3390/medsci12010016","DOIUrl":"https://doi.org/10.3390/medsci12010016","url":null,"abstract":"Background: Pituitary adenomas are benign brain tumors that impose a heavy burden on patients worldwide. The local burden of disease is yet to be established due to scarcity of data. In line with this, this study aims to present the challenges and gaps in the treatment of pituitary adenomas in the Philippines. Methods: A scoping review of available relevant literature on epidemiology, clinical experience with treatment, health financing, and healthcare delivery system based on the Preferred Reporting Items for Systematic reviews and Meta-analysis guidelines extension for Scoping Reviews was conducted. Results: The scarcity of updated local clinical data, inequity of distribution of resources, inadequate government support, and lack of affordable diagnostic testing, medications, and neurosurgical procedures are the factors that hinder provision of adequate care of pituitary adenomas in the Philippines. Conclusion: There are notable treatment gaps in the management of pituitary adenomas in the Philippines, which may be addressed by strengthening universal healthcare. Strategies to address these gaps were proposed, including improving public-private insurance coverage, increasing manpower, enhancing accessibility to resources, and spreading more awareness.","PeriodicalId":18539,"journal":{"name":"Medical Sciences","volume":"105 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140228356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1